Background Gastrointestinal stromal tumours (GIST) are histologically heterogenous group of mesenchymal tumours arising in gastrointestinal tract (GIT), though they represent only 0.2% of all GI tumours. The advent of effective chemotherapy for GIST has altered but not diminished the role of surgery which remains the standard therapy for all resectable non-metastatic tumours.
Introduction
Gastrointestinal stromal tumours (GIST) are a histologically heterogenous group of mesenchymal tumours that arise in the gastrointestinal tract (GIT). They are the most common sarcomas of the GIT commonly seen in stomach and small bowel, though they represent only 0.2% of all GI tumours [1] . These tumours were thought to be of smooth muscle origin and due to its uncertain prognosis, the term 'STUMP' (smooth muscle tumours of uncertain malignant potential) was used. They were also called 'GANT' (gastrointestinal autonomic nerve tumours) because of the similarity of their cells to neural cells in the autonomic myenteric plexus [2, 3] . The term GIST was previously used to describe any mesenchymal tumour of GIT [4] . GIST is currently defined as CD117 positive (more than 10% tumour cells positive), spindle cell or epitheloid cell neoplasms [5, 6] . GISTs are mostly clinically silent until they grow large, bleed or rupture [7, 8] . GIST may be detected incidentally following endoscopy, imaging or surgery in about 41-63% cases [9, 10] . A dramatic change in the treatment of GIST occurred following the recognition that ORIGINAL ARTICLE activated KIT provided the driving force for GIST growth, and this led to the use of imatinib mesylate (Gleevec/ Glivec) as targeted therapy. The advent of effective chemotherapy for GIST has altered but not diminished the role of surgery which remains the standard therapy for all resectable non-metastatic tumours. Guidelines for chemotherapy have been changing. Currently as per NCCN 2008, chemotherapy has been recommended in a postoperative setting for intermediate and high risk groups following curative resection. The 5-year overall survival rates following complete resection of localised GIST, range from 40 to 55% [11, 12] . Controversy exists over conservative management of small sized tumours, however the recognition that even small sized GIST can exhibit aggressive behaviour, leads most surgeons to recommend excision of all tumours, in patients who are acceptable operative candidates.
Materials and methods
We studied all cases of GIST managed at our centre from April 2006 to June 2008. All patients were evaluated by clinical examination and by imaging, using USG abdomen initially followed by CECT abdomen, besides immunohistochemistry studies in last four cases as the same was not available earlier. All patients were offered surgery as the primary modality of treatment. Patients who were in the high risk group (NCCN 2007) and those positive for CD117 were offered postoperative chemotherapy in the form of imatinib mesylate. Patients were kept on regular follow up with 6 monthly clinical examination and USG abdomen.
Results
Thirteen cases of GIST were operated in the study period. Mean age at presentation was 46.2 years (28-70 years); male-to-female ratio was 10:3. Presenting symptoms were lump abdomen and dull abdominal pain in nine cases, recurrent lower GI bleed in one case, anaemia in one case, incidental in one case and malena in one case. After initial USG evaluation, CECT was done in all cases for better localisation. At surgery, tumour was seen to arise from small bowel in 7 out of 13 cases (duodenum -1, jejunum -3, ileum -3), from stomach in 4 out of 13 cases (Fig.  1) and one each from oesophagus and omentum (Fig.  2) . Resection and anastamosis was done in 10/13 cases (Fig. 3) , one case of posterior wall stomach GIST underwent sleeve resection, omental GIST underwent omentectomy and one case was found to be inoperable at surgery as the tumour was encasing the superior mesenteric artery pedicle and splenic vein, and infiltrating into pancreas and retroperitoneum. Histopathological examination confirmed diagnosis of GIST in all cases. Immunohistochemistry studies were done in last four cases out of the 13 cases. Out of the 13 cases, one case was in the high risk group and one case was unresectable. Both of these patients were offered postoperative chemotherapy in the form of imatinib mesylate conforming to NCCN 2007 guidelines. On follow up, the patient with unresectable tumour has shown partial response and the patient in high risk group has shown no recurrence.
Discussion
GIST are rare malignancies even though they are the most common sarcoma of the GIT. Majority of GIST occur in
